Editorials

Valuing the effects of sildenafil in erectile dysfunction

BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7243.1156 (Published 29 April 2000) Cite this as: BMJ 2000;320:1156

Strong assumptions are required to generate a QALY value

  1. Nick Freemantle, reader in epidemiology and biostatistics. (meg@york.ac.uk)
  1. Medicines Evaluation Group, Centre for Health Economics, University of York, York YO10 5DD

    Papers p 1165

    Sildenafil is a true breakthrough drug in the sense that it provides a potential treatment for a condition for which there was no existing acceptable alternative. This complicates any attempt to describe the cost effectiveness of sildenafil in erectile dysfunction, such as that by Stolk et al in this week's BMJ (p 1165).1 They compare sildenafil with papaverine-phentolamine injections, which they argue are rationed on “medical grounds” and will not achieve the population benefits that might be achieved by sildenafil. More controversially, they argue that “the incremental cost-effectiveness of sildenafil lies at the favourable end of the scale when compared with interventions in health care for other diseases.”

    The comparator therapy Stolk et al refer to, papaverine-phentolamine injections, seems not to have been rigorously evaluated and is not widely used. They used a cost utility approach in which a representative sample of the general population were asked to value the effects of treatment (for a condition that they did not have) to generate a cost per quality adjusted life year (QALY). Why might we question the validity of these findings?

    Generating values for …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe